The association of baseline IL-1β levels with irAE is particularly interesting, because it had not been reported in NSCLC patients before, and because the IL-1β inhibitor canakinumab and other IL-1 drugs are widely, in part off-label, used to treat a variety of mainly autoinflammatory disorders in rheumatology (56). The gene discussed is IL1B; the disease is non-small cell lung carcinoma.